1. Problem Statement

Core treatment goals of the Vien gut Model – crystal-free in complicated gout (Goal 1), delaying dialysis (Goal 2), reducing cardiovascular decompensation (Goal 3), liver cirrhosis recompensation (Goal 4) – can only be pursued effectively when patients are approached through the WHAT–HOW–DATA-to-operate treatment model. This mindset aligns with NICE’s spirit on multimorbidity: not mechanically adding single-disease guidelines, but optimizing care, reducing treatment burden, and having a clear coordinator for each patient. [4]

Therefore, these treatment goals are not set after several fragmented consultations but must be initiated from the very first visit. The first consultation must be the trigger for the entire integrated operational system – a relatively comprehensive examination and diagnosis, identifying pathological loops, and stratifying patients by treatment safety levels to choose the appropriate management direction from the start. [5]

2. Ultimate Goal: An Integrated Clinical Picture

The first consultation must create an integrated clinical picture of the entire patient – deep enough to determine: which disease is the primary one and which comorbidities are dominant; which target organs are damaged and to what extent; which disease-disease and disease-drug interactions are creating a loop; which factors in real life are continuing to worsen the condition (corticoid dependence, poor compliance, previous fragmented treatment). From there, the Clinical Conductor activates the integrated treatment plan, assigns the MDT, and establishes an appropriate longitudinal monitoring rhythm. [5]

WHAT (Guideline)	HOW (Vien gut Supplement)
Set treatment goals by single diseases	Activate the integrated operational system from the first visit
Recommend periodic monitoring but without designing an operational mechanism	Establish an integrated clinical picture across all four target organ axes
No guidance for multidisciplinary coordination in complex outpatient settings	Stratify T1–T4, assign Clinical Conductor, build individualized plans

[6]

3. Three Patient Zones and Deep Branching Mechanism

The Vien gut Model simultaneously addresses three zones: Zone 1 (within guideline coverage – direct application, HOW organizes standard execution), Zone 2 (borderline – multimorbidity, polypharmacy, HOW must resolve conflicts), Zone 3 (outside guideline coverage but still meeting outpatient criteria – HOW must be strongest). Note: “outside guideline coverage” does not mean “outside standard of care” – it means stronger HOW is needed to maintain the safety margin. [6]

The first visit is a broad consultation with a clinical orientation. The 4 validation axes (gout, kidney, heart, liver) are the output measurement framework – not 4 mandatory exploratory packages. An axis is only deeply activated when the patient has a clear clinical reason. Layer 1 (invariant): detect vital factors, build the overall picture, stratify T1–T4. Layer 2: open deep branches by axis when clinical indicators are present. [7]

4. Five Principles of Indication and Minimum Paraclinical Core

Five principles of indication in the first consultation: [7]

Principle	Content
1	Not every patient is examined the same – deep indications must follow the specific disease, symptoms, and risks of each patient.
2	All deep paraclinical indications must adhere to updated guidelines: gout follows ACR/EULAR, kidney follows KDIGO, heart follows ESC, liver follows EASL/AASLD.
3	The minimum paraclinical core is the system safety core, not a core for examining all four axes.
4	Each test must be accompanied by a clear management branch: who is responsible, reaction threshold, next management branch.
5	No over-indication (increased cost, burden), and no under-indication (missing target organ damage).

[8]

The minimum paraclinical core includes three layers: [9]

Layer	Content
General Safety Core (Mandatory for all)	CBC, Creatinine/Urea/eGFR, Electrolytes (Na⁺ K⁺ Cl⁻ HCO₃⁻), Urinalysis, AST/ALT/Bilirubin/Albumin, Blood pressure measurement, Full drug history review, Glucocorticoid exposure screening
Risk-based Supplement	Glucose/HbA1c (suspected DM), PT/INR (suspected severe liver disease), Uric acid (history of gout), ECG (CV risk, CKD), Proteinuria/Albuminuria (abnormal eGFR)
Deep Branch Opening when Axis is Triggered	Joint Ultrasound/DECT (Gout axis), Renal Ultrasound (Kidney axis), TTE + Chest X-ray (Heart axis), Abdominal Ultrasound + Elastography (Liver axis), Endocrine tests (only when clinically suspected)

[9]

The paraclinical core is compatible with NICE (reducing fragmented care) and KDIGO 2024 (eGFR + albuminuria are the two core axes for kidney risk assessment). Expansion principle: uric acid does not automatically mean opening the deep gout axis; ECG does not mean immediate heart ultrasound – only open when the axis is activated by the disease, typical symptoms, or major abnormalities on the screening layer. This is how to both stay true to guidelines and avoid both over- and under-indication. [10]

5. T1–T4 Stratification and the Clinical Conductor

From the integrated clinical picture, the Clinical Conductor stratifies risk into T1–T4: T1 (stable, guidelines are sufficient), T2 (complex, requires enhanced HOW), T3 (high risk, full HOW + referral valve on standby), T4 (critical, needs immediate referral evaluation). Stratification determines: follow-up rhythm, monitoring intensity, MDT mobilization level, and referral valve status. [10]

The Clinical Conductor does more than just aggregate results or sign indications. From the very first visit, this person must answer: which disease takes priority, which loop must be unraveled first, is there any guideline conflict needing immediate resolution, and is the treatment intensity within the safety margin. All workflow converges at the Clinical Conductor to move from “knowing a lot of data” to “making an integrated clinical decision.” [11]

The role of HOW and DATA-to-operate in the first visit is particularly important. HOW establishes the workflow: who examines first, who follows, what line the information follows, and who makes the final decision. DATA-to-operate ensures that every piece of data collected has a clear action threshold: if a test result exceeds the threshold, the system must know who receives the information, within what timeframe, and the reaction according to the scenario. Without this layer, data is just numbers in a file – it does not become clinical action. [11]

6. Multidisciplinary Team (MDT) and the Referral Valve

The MDT in the first visit must operate as a sensor-response chain with clear assignments: [12]

MDT Position	Sensor-Response Role
Radiologist	Turns imaging into a longitudinal structure-function monitoring tool
Lab Personnel	Turns tests into a radar to identify breakpoints and threshold sliding trends
Clinical Pharmacist	Safety checkpoint for polypharmacy, drug interactions, and medication guidance
Nurse / Monitoring Staff	Implements checklists, detects red signals, coordinates follow-ups/referrals
Visual Medicine Staff	Standardizes before-after photos/videos; reinforces trust and compliance
Data/Ops Department	Trend dashboards, breakpoint reminders, supporting decision log/audit trail

[12]

It is this sensor-response chain that makes HOW operational in reality. MDT members do not work in isolation but operate within a two-way information flow: from the field to the Clinical Conductor, and from the Clinical Conductor to the execution points. [13]

A safe referral valve must be established from the first visit – not built only when the patient decompensates. If stratification shows the patient is T3–T4, the valve must be on standby: clear activation path, data handover protocol ready, and preparations for post-inpatient reintegration. This is not a failure of outpatient care but a condition for integrated outpatient care to dare to keep patients who still have a window of opportunity. [13]

Referral valve mechanisms include: Clinical Conductor confirms the referral decision and prioritizes protecting vital organs; nurses organize urgent triage; lab and imaging prioritize returning critical data; clinical pharmacists review medications and related risks; outpatient care prepares for post-inpatient reintegration; data/ops complete the decision log and handover dataset. On the heart axis, the 2021 chest pain guideline requires a standardized pathway to quickly recognize life-threatening situations; on the liver and kidney axes, guidelines emphasize early recognition of decompensation to trigger timely responses. [14]

7. Patient Education and Compliance Assessment

From the first visit, the system must assess the patient’s capacity to participate and begin building necessary conditions: minimum operational knowledge, self-awareness, ability to follow the follow-up rhythm, and acceptance of the referral valve. Patient education is not a supplementary activity but a mandatory component of HOW – because in complex multimorbidity, the interval between visits is a “shared responsibility zone” between the model and the patient. [15]

Assessing compliance with treatment discipline is not a moral check but an operational check: is the patient taking medication correctly, testing at the right milestones, and reporting early signs of abnormality? When a break in compliance is detected, the system reacts with intensified education and contact frequency – not with judgment. Reality is not ideal: patients may be tired, discouraged, lacking resources, or following word-of-mouth advice outside the model. HOW must be designed to operate in that non-ideal environment. [15]

8. Clinical Illustration – Case DTH

The first consultation at Vien gut (04/01/2021) detected decompensated F4 liver cirrhosis Child-Pugh B7 caused by Alcohol-related Liver Disease (ALD): GGT 397.1 U/L (>7x threshold), AST/ALT >2, HBsAg negative, Anti-HCV negative. None of the 5 previous facilities – over many years – had diagnosed ALD, initiated alcohol cessation intervention, or provided structured nutrition counseling. Identifying the correct cause from the first session opened the entire intervention chain: total alcohol cessation, structured nutrition, phase-based Fibroscan monitoring. Results after 4 years: GGT 397.1 → 87.1 U/L, Fibroscan 23 → 11 kPa (F4 → F3), grade III splenomegaly completely regressed. [16]

9. Comparison with the Fragmented Model

International evidence (NICE NG56, Hughes 2013, Muth 2019, JA-CHRODIS, Jiang 2023) confirms: the fragmented model – where each specialist handles a single disease separately with no integrated coordination – causes excessive treatment burden, unresolved goal conflicts, increased emergency visits, increased diagnostic test usage, and increased total medical costs. [17]

In the first consultation under a fragmented model, the receiving specialist usually only records symptoms belonging to their specialty, orders tests per single-disease guidelines, and schedules a follow-up – with no integrated picture, no multi-axis stratification, and no Clinical Conductor holding the overview. Specific consequences from the DTH case: over 20 years across 5 medical facilities, four life-saving interventions were consistently missed – secondary adrenal insufficiency, ALD diagnosis, hyperkalemia, and integrated polypharmacy management. This is not a personal error but an architectural limitation. [17]

The Vien gut Model designs the first visit as the system trigger – as this is the only opportunity to set the right foundation for the entire long-term treatment journey. When this foundation is not established from the start, all subsequent treatment efforts are built on an unstable base – and the patient pays with missed windows of opportunity, unraveled pathological loops, and preventable multi-organ decompensation. [18]

Evidence Level: Level IV – proof-of-concept. Full data: DTH Case Report v5.4 CARE (Vien gut, 2026). [18]

Full Document: B.1 – The First Consultation (16 items, 17 pages). [19]